Journal: AIDS Research and Human Retroviruses

Article Title: HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry

doi: 10.1089/aid.2009.0132

Figure Lengend Snippet: (A) Infection of U87/CD4/CCR5 and U87/CD4/CXCR4 cells with pseudotyped viruses bearing representative pretreatment and posttreatment Envs cloned from P5. The dual-tropic R3A env was included as a positive control. (B) Infection of CD4+ T cells from a CCR5-Δ32 homozygous normal donor with viruses pseudotyped with envs from P5 and the R3A control. Pseudoviruses bearing envs from P5 are unable to use CXCR4 for entry on primary cells. These data are the result of three independent experiments.

Article Snippet: CD4 + T cells isolated from leukophereses (RosetteSep CD4 + T-cell kit; Stemcell Technologies) were stimulated at 4 × 10 6 cells/ml with 1 μl/ml anti-CD3 (eBioscience), 1 μl/ml anti-CD28 (Becton Dickinson), and 20 U/ml of interleukin-2 (IL-2, Sigma) for 3 days.

Techniques: Infection, Clone Assay, Positive Control

Journal: AIDS Research and Human Retroviruses

Article Title: HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry

doi: 10.1089/aid.2009.0132

Figure Lengend Snippet: Infection of U87/CD4/CCR5 cells with pseudoviruses cloned with envs from P5 from (A) pretreatment and (B) posttreatment time points in the presence of APL. Infection of (C) 293/CD4/CCR5 and (D) NP2/CD4/CCR5 cell lines in the presence of APL. The maximal percent inhibitions (MPI) of each virus are listed in parentheses following the Env designation. Viruses pseudotyped with Envs from P5 demonstrate varying plateau levels to aplaviroc on different cell types. These data are the result of four independent experiments.

Article Snippet: CD4 + T cells isolated from leukophereses (RosetteSep CD4 + T-cell kit; Stemcell Technologies) were stimulated at 4 × 10 6 cells/ml with 1 μl/ml anti-CD3 (eBioscience), 1 μl/ml anti-CD28 (Becton Dickinson), and 20 U/ml of interleukin-2 (IL-2, Sigma) for 3 days.

Techniques: Infection, Clone Assay

Journal: AIDS Research and Human Retroviruses

Article Title: HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry

doi: 10.1089/aid.2009.0132

Figure Lengend Snippet: Infection of Primary CD4 + T Cells from Normal Donors

Article Snippet: CD4 + T cells isolated from leukophereses (RosetteSep CD4 + T-cell kit; Stemcell Technologies) were stimulated at 4 × 10 6 cells/ml with 1 μl/ml anti-CD3 (eBioscience), 1 μl/ml anti-CD28 (Becton Dickinson), and 20 U/ml of interleukin-2 (IL-2, Sigma) for 3 days.

Techniques: Infection

Journal: AIDS Research and Human Retroviruses

Article Title: HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry

doi: 10.1089/aid.2009.0132

Figure Lengend Snippet: Infection of U87/CD4/CCR5 cells in the presence of the CCR5 antagonists (A) AD101, (B) CMPD167, (C) TAK779, (D) maraviroc, and (E) the fusion inhibitor enfuvirtide. Viruses pseudotyped with envs from P5 are resistant to complete suppression by AD101, CMPD167, and TAK779 but are sensitive to maraviroc and enfuvirtide. (F) Infection of NP2/CD4/CCR5 cells in the presence of maraviroc. Percent inhibition values at 10 μM AD101, CMPD167, TAK779, 1 μM maraviroc, and 62.5 μg/ml of enfuvirtide are listed in parentheses following the Env designation. These data are the result of three independent experiments.

Article Snippet: CD4 + T cells isolated from leukophereses (RosetteSep CD4 + T-cell kit; Stemcell Technologies) were stimulated at 4 × 10 6 cells/ml with 1 μl/ml anti-CD3 (eBioscience), 1 μl/ml anti-CD28 (Becton Dickinson), and 20 U/ml of interleukin-2 (IL-2, Sigma) for 3 days.

Techniques: Infection, Inhibition

Journal: AIDS Research and Human Retroviruses

Article Title: HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry

doi: 10.1089/aid.2009.0132

Figure Lengend Snippet: (A) Chemokine inhibition of HIV infection in primary CD4+ T cells from two normal donors pretreated with APL. Cells were pretreated with no or 1 μM APL, followed by stimulation with 50 nM CCL3, CCL4, and CCL3L1 prior to infection with viruses bearing Env pre5.2. Pretreatment with APL completely blocked the inhibitory effects of chemokines on HIV infection. These data are the result of two independent experiments for each donor. (B) Maraviroc inhibition of pseudoviruses bearing Env pre5.2 in the presence or absence of 100 nM aplaviroc on NP2/CD4/CCR5 cells. Higher concentrations of maraviroc were required to reach plateau levels and 50% of the maximal inhibitory potential in the presence of 100 nM APL than in its absence. These data suggest that pre5.2 Env can utilize both aplaviroc- and maraviroc-bound CCR5 but uses the former more efficiently. These results are from three independent experiments.

Article Snippet: CD4 + T cells isolated from leukophereses (RosetteSep CD4 + T-cell kit; Stemcell Technologies) were stimulated at 4 × 10 6 cells/ml with 1 μl/ml anti-CD3 (eBioscience), 1 μl/ml anti-CD28 (Becton Dickinson), and 20 U/ml of interleukin-2 (IL-2, Sigma) for 3 days.

Techniques: Inhibition, Infection

Journal: Clinical and Developmental Immunology

Article Title: Cysticerci Drive Dendritic Cells to Promote In Vitro and In Vivo Tregs Differentiation

doi: 10.1155/2013/981468

Figure Lengend Snippet: In vitro differentiation of dendritic cells in the presence of Taenia solium or T. crassiceps cysticerci promotes Treg induction. (a) Increased percentage in Treg cell induction. Percentage was calculated as follows: (percentage of Tregs induced/percentage of basal Tregs) × 100. Different letters indicate significant differences between groups at P < 0.05. (b) Representative histograms showing Foxp3 induction within CD4 + CD25 high cells. Data are representative of three independent experiments.

Article Snippet: A RosetteSep Human CD4 + T Cell Enrichment Cocktail kit was used for CD4 + T cell purification (StemCell, Vancouver, Canada).

Techniques: In Vitro

Journal: Clinical and Developmental Immunology

Article Title: Cysticerci Drive Dendritic Cells to Promote In Vitro and In Vivo Tregs Differentiation

doi: 10.1155/2013/981468

Figure Lengend Snippet: Levels of cytokines in supernatants from in vitro DC differentiation and in vitro regulatory T cell induction.

Article Snippet: A RosetteSep Human CD4 + T Cell Enrichment Cocktail kit was used for CD4 + T cell purification (StemCell, Vancouver, Canada).

Techniques: In Vitro

Journal: Clinical and Developmental Immunology

Article Title: Cysticerci Drive Dendritic Cells to Promote In Vitro and In Vivo Tregs Differentiation

doi: 10.1155/2013/981468

Figure Lengend Snippet: Phenotype of peripheral dendritic and regulatory T cells in NC patients and healthy subjects.

Article Snippet: A RosetteSep Human CD4 + T Cell Enrichment Cocktail kit was used for CD4 + T cell purification (StemCell, Vancouver, Canada).

Techniques: